← Back to Search

Markers for Primary Immunodeficiency

N/A
Waitlist Available
Research Sponsored by Meyer Children's Hospital IRCCS
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Clinical and hematological diagnosis of autoimmune cytopenia
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up every three to six months
Awards & highlights

Summary

This trial aims to better understand and find effective treatments for autoimmune cytopenias, which are common in patients with immune system disorders. Current treatments often fail, leading to high costs and health risks. The

Who is the study for?
This trial is for patients with autoimmune cytopenias, which include conditions like low platelet count, anemia, and low white blood cell count that are resistant to treatment. These patients may also have primary immunodeficiencies (PI).
What is being tested?
The study aims to identify specific early biomarkers in the immune system that can help diagnose autoimmune cytopenias and predict who will respond well to therapy.
What are the potential side effects?
Since this trial focuses on identification of biomarkers rather than testing a drug or medical intervention, there are no direct side effects associated with the interventions being studied.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with a blood disorder where my immune system attacks my blood cells.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~every three to six months
This trial's timeline: 3 weeks for screening, Varies for treatment, and every three to six months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Identification of specific markers

Trial Design

1Treatment groups
Experimental Treatment
Group I: Identification of specific markersExperimental Treatment1 Intervention
Analysis of the immunological profile, Genetic analysis using next-generation sequencing (NGS) technology, Bioinformatic analysis, Functional studies.

Find a Location

Who is running the clinical trial?

Meyer Children's Hospital IRCCSLead Sponsor
39 Previous Clinical Trials
12,840 Total Patients Enrolled
~2 spots leftby Dec 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top